Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07307612 · ClinicalTrials.gov registry record · Phase 1
High-energy Human Milk Diets in the First Two Weeks After Birth to Reduce BPD in Extremely Preterm Infants
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Not yet
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
NCT07307612 is a Phase 1 study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 150 participants.
The verdict
NCT07307612, a Phase 1 study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
Study Summary
This Phase II, parallel-group, masked, randomized clinical trial aims to evaluate whether a DHA/ARA-enriched, fortified human milk diet administered during the first 14 days of life reduces respiratory morbidity and improves lung function in extremely preterm (EPT) infants (born at ≤28 weeks gestation).
Interventions
- DIETARY_SUPPLEMENT High-energy group
- OTHER Standard-energy group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-08-15 |
| Est. Completion | 2029-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07307612
The ClinicalTrials.gov registry entry for NCT07307612 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which High-energy group is the first listed.
NCT07307612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07307612 about?
NCT07307612 is a clinical study titled "High-energy Human Milk Diets in the First Two Weeks After Birth to Reduce BPD in Extremely Preterm Infants". This Phase II, parallel-group, masked, randomized clinical trial aims to evaluate whether a DHA/ARA-enriched, fortified human milk diet administered during the first 14 days of life reduces respiratory morbidity and improves lung function in extremely preterm (EPT) infants (born at ≤28 weeks gestati...
What is the current status of trial NCT07307612?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2026-08-15. Estimated completion is 2029-07-31.
What interventions are being tested in trial NCT07307612?
The interventions under investigation include: High-energy group (DIETARY_SUPPLEMENT), Standard-energy group (OTHER).
Who is sponsoring clinical trial NCT07307612?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.